Predictive Markers for Dasatinib to Treat Solid Tumors
Predicts efficacy and response of dasatinib therapy on triple negative breast cancer subtypes Genes expressed in patients with specific breast cancer subtypes may be sensitive to therapy with SRC kinase inhibitors Predictive markers may be used in clinical development of compounds to treat solid tumors
Use markers to identify individuals who are likely to respond, or are responsive, to therapy with dasatinib or other SRC kinase inhibitors Predict response of dasatinib to treat the triple negative subset of women with breast cancer
UCLA researchers have identified predictive markers to identify human breast cancer cells that are likely to respond to dasatinib or to therapy with another SRC kinase inhibitor. This unique gene set has been identified by using an in vitro pharmocogenomic approach.
Patent Number: US8007995B2
Application Number: US200893042A
Inventor: Finn, Richard S. | Dering, Judy | Slamon, Dennis J. | Ginther, Charles L. | Clark, Edwin A.
Priority Date: 10 Nov 2005
Priority Number: US8007995B2
Application Date: 29 Oct 2008
Publication Date: 30 Aug 2011
IPC Current: C12Q000100 | C12Q000168 | G01N003353 | G01N0033574
US Class: 435004 | 43500611 | 4350071 | 43500721 | 43500723 | 435006
Assignee Applicant: Bristol-Myers Squibb Company,Princeton | The Regents of the University of California
Title: Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
Usefulness: Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
Summary: The method is useful for determining the responsiveness of a mammalian tumor cell or an individual with cancer, where the tumor cell is a breast cell. The breast cell is basal cell, luminal cell, mesenchymal cell, breast cancer associated gene-1 (BRCA-1) cell, cell that has undergone an epithelial to mesenchymal transition, or cell that reduced expression of an estrogen, progesterone, and herceptin (HER)-2 receptor. The cancer is breast cancer. The tumor is a breast cancer tumor. The method (M1) is useful for treating an individual suffering from cancer (all claimed).
Novelty: Detecting tumor cell responsiveness to treatment with specific thiazolecarboxamide compound, involves determining expression level of a gene chosen from moesin, caveolin-1 or yes-associated protein-1 in tumor cell
诊断/治疗
癌症/肿瘤
8007995
State of Development Inventors have employed the approach in human breast cancer cell lines in vitro. These markers will need to be validated in a clinical setting. Background Cancer is one of the leading causes of death worldwide, killing millions of people every year. Of the different types of cancers, breast cancer is the leading cause of death among women, affecting over one million women worldwide every year. Currently, dasatinib is approved to treat chronic myeloid leukemia (CML) and is in development to treat solid tumors, including breast cancer. However, there is a need to be able to identify patients most likely to respond to drugs like dasatinib. New diagnostics methods will be especially useful for women whose breast cancers fall under a specific triple negative subtype (estrogen receptor negative, progesterone receptor negative, and HER2 negative), and therefore lack effective treatments. Due to the lack of effective treatments, there is a need to identify the patients that might benefit from dasatinib. Related Materials Additional Technologies by these Inventors Tech ID/UC Case 20277/2006-263-0 Related Cases 2006-263-0
美国
